Clene Inc. Common Stock (CLNN)
Stock · NASDAQ · Health Care
$3.12as of 10/16/2026
Price chart
Active signals
CLNN Signal Track Record
How signals performed across all stocks →What CLNN's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 40 | -3.0% | 48% | September 1, 2026 |
| Bollinger Band BreakdownActive now | 27 | +2.9% | 56% | September 8, 2026 |
| Bollinger Band Breakout | 20 | -16.6% | 30% | June 29, 2026 |
| 200-Day Moving Average TouchActive now | 7 | -8.2% | 29% | May 19, 2026 |
| Any 20-session window (baseline) | -5.4% | 39% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About CLNN
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The company's lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); comp…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 76
- Website
- clene.com/
Fundamentals
- 1-day range
- $3.06$3.33
- Market cap
- $68.24M
- P/E (trailing)
- —
- P/E (forward)
- -1.29
- EPS (trailing)
- $-3.49
- Dividend yield
- —
- Beta
- 1.07
- Avg. volume
- 101.9K
How Clene Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 17, 2026 · via SEC EDGAR / Finnhub
Forecasts
5 analyst ratings
Clene Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- CLNNClene Inc. Common Stock$3.1▼ 6.34%Market cap $68.24MP/E —$3.24$13.5
- CINGCingulate Inc. Common Stock$4.36▼ 0.68%Market cap $68.02MP/E —$3.16$11.89
- RNTXRein Therapeutics Inc. Common Stock$0.59▼ 6.05%Market cap $67.45MP/E —$0.5401$2.18
- IBIOiBio Inc. Common Stock$0.77▼ 1.28%Market cap $69.05MP/E —$0.7328$3.82
- XBITXBiotech Inc. Common Stock$2.12▼ 1.85%Market cap $69.51MP/E —$2.09$3.44
- MNOVMedicinova Inc Common Stock$1.42▼ 2.07%Market cap $66.94MP/E —$1.17$3.9
- INOInovio Pharmaceuticals Inc. Common Stock$0.99▼ 4.81%Market cap $69.62MP/E —$0.5632$2.72
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| CLNN Clene Inc. Common Stock | $68.24M | — | $3.1 | ▼ 6.34% | $3.24$13.5 |
| CING Cingulate Inc. Common Stock | $68.02M | — | $4.36 | ▼ 0.68% | $3.16$11.89 |
| RNTX Rein Therapeutics Inc. Common Stock | $67.45M | — | $0.59 | ▼ 6.05% | $0.5401$2.18 |
| IBIO iBio Inc. Common Stock | $69.05M | — | $0.77 | ▼ 1.28% | $0.7328$3.82 |
| XBIT XBiotech Inc. Common Stock | $69.51M | — | $2.12 | ▼ 1.85% | $2.09$3.44 |
| MNOV Medicinova Inc Common Stock | $66.94M | — | $1.42 | ▼ 2.07% | $1.17$3.9 |
| INO Inovio Pharmaceuticals Inc. Common Stock | $69.62M | — | $0.99 | ▼ 4.81% | $0.5632$2.72 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Clene Targets Q4 FDA Filing for ALS Drug CNM-Au8, Eyes Mid-2027 DecisionYahoo · 10/2/2026
- Clene to Present at Upcoming Investor ConferencesYahoo · 9/22/2026
- Clene Announces Closing of $4 Million Registered Direct Offering Extending Capital Runway Beyond FDA Decision on CNM-Au8® NDAYahoo · 9/21/2026
- 12 Health Care Stocks Moving In Tuesday's Intraday SessionBenzinga · 9/15/2026
- Clene Announces $4 Million Registered Direct OfferingYahoo · 9/15/2026
- Clene Prices Registered Direct Offering Of 1,219,513 Shares At $3.28/Shr To Existing Shareholders With Total Gross Proceeds Of $4MBenzinga · 9/15/2026
Insider Activity
Insider Actions →- Etherington Robert Dee · September 16, 2026 · Grant15.2K @ $3.28
- Alison Mosca · September 16, 2026 · Grant198.2K @ $3.28
- David J. Matlin · September 16, 2026 · Grant434.5K @ $3.28
- Kiernan Matthew · August 13, 2026 · Grant3.2K
- Desai Arjun JJ · August 13, 2026 · Grant3.7K
- Alison Mosca · August 13, 2026 · Grant4.9K
- McLaughlin Vallerie · August 13, 2026 · Grant3.5K
- WILCOX REED N · August 13, 2026 · Grant3.5K
- David J. Matlin · August 13, 2026 · Grant6.2K
- Jacobovitz Shalom · August 13, 2026 · Grant4.8K
- Gay Jonathon · August 13, 2026 · Grant3.8K
- Chidozie Ugwumba · July 17, 2026 · J424.4K
- Chidozie Ugwumba · July 17, 2026 · J375.0K
- Mortenson Mark · June 11, 2026 · Grant45.0K
- Etherington Robert Dee · June 11, 2026 · Grant65.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 2.14M
- Total value held
- $10.57M
- Institutional holders
- 27
- Unknown477.5K
- Unknown431.1K
- Unknown308.2K
- Unknown300.0K
- Unknown257.9K
- Unknown95.9K
- Unknown52.3K
- Unknown50.0K
- Unknown37.2K
- Unknown33.8K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Clene to Present at Investor Conferences
Clene Inc. announced it will present at several upcoming investor conferences. The company will use the events to share updates on its operations and strategy. The announcement is a routine corporate event that may increase visibility among investors.
Clene to Present at Investor Conferences. Clene Inc. announced it will present at several upcoming investor conferences. The company will use the events to share updates on its operations and strategy. The announcement is a routine corporate event that may increase visibility among investors.